Phase II Study of Oral S-1 and Concurrent Radiotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer
| Autor: | Toshiyuki Imagumbai, Taketo Yamaguchi, Mitsuhiro Sakai, Takeshi Ishihara, Taro Hara, Hitoshi Araki, Kentaro Sudo, Osamu Yokosuka, Hisao Ito, Tadamichi Denda, Kazuo Hatano, Kazuyoshi Nakamura, Hiroyuki Kawakami, Katsunobu Tawada, Takashi Uno |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Pancreatic disease CA-19-9 Antigen Combination therapy medicine.medical_treatment Phases of clinical research Deoxycytidine Gastroenterology Drug Administration Schedule Internal medicine Pancreatic cancer medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Survival rate Aged Tegafur Radiation business.industry Cancer Nausea Radiotherapy Dosage Middle Aged medicine.disease Combined Modality Therapy Gemcitabine Anorexia Surgery Pancreatic Neoplasms Radiation therapy Drug Combinations Oxonic Acid Oncology Disease Progression Female business Chemoradiotherapy |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 80:119-125 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2010.01.027 |
| Popis: | Purpose S-1 is an oral fluoropyrimidine derivative that has demonstrated favorable antitumor activity in patients with metastatic pancreatic cancer. The aim of this study was to evaluate safety and efficacy of S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Methods and Materials Patients with histopathologically proven, unresectable, locally advanced pancreatic cancer were eligible. Radiotherapy was delivered in 1.8 Gy daily fractions to a total dose of 50.4 Gy over 5.5 weeks. S-1 was administered orally twice a day at a dose of 80 mg/m 2 /day from day 1 to 14 and 22 to 35. Two weeks after the completion of chemoradiotherapy, maintenance chemotherapy with S-1 was administered for 28 days every 6 weeks until progression. Results Thirty-four patients were enrolled in this study. The most common Grade 3 toxicities during chemoradiotherapy were anorexia (24%) and nausea (12%). The overall response rate was 41% (95% confidence interval, 25%–58%) and overall disease control rate (partial response plus stable disease) was 97%. More than 50% decrease in serum CA 19-9 was seen in 27 of 29 evaluable patients (93%). The median progression-free survival was 8.7 months. The median overall survival and 1-year survival rate were 16.8 months and 70.6%, respectively. Conclusions Oral S-1 and concurrent radiotherapy exerted a promising antitumor activity with acceptable toxicity in patients with locally advanced pancreatic cancer. This combination therapy seems to be an attractive alternative to conventional chemoradiotherapy using 5-fluorouracil infusion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|